Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGEM 
Cullinan Oncology LLC (CGEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: CGEM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $26.22
1 Year Target Price $26.22
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.04% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 449.56M USD | Price to earnings Ratio - | 1Y Target Price 26.22 |
Price to earnings Ratio - | 1Y Target Price 26.22 | ||
Volume (30-day avg) 9 | Beta -0.07 | 52 Weeks Range 6.85 - 19.89 | Updated Date 08/29/2025 |
52 Weeks Range 6.85 - 19.89 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.16 |
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.82 | Actual -1.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.42% | Return on Equity (TTM) -36.01% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 185593115 | Price to Sales(TTM) 26.88 |
Enterprise Value 185593115 | Price to Sales(TTM) 26.88 | ||
Enterprise Value to Revenue 11.55 | Enterprise Value to EBITDA -1.46 | Shares Outstanding 59074400 | Shares Floating 36054873 |
Shares Outstanding 59074400 | Shares Floating 36054873 | ||
Percent Insiders 4.54 | Percent Institutions 107.58 |
Upturn AI SWOT
Cullinan Oncology LLC
Company Overview
History and Background
Cullinan Oncology, Inc. is a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for cancer patients. Founded in 2016 by biotech entrepreneur Dr. Christoph Lengauer, the company has evolved through various stages of preclinical and clinical development of its drug candidates. The company went public in January 2021.
Core Business Areas
- Drug Development: Cullinan Oncology focuses on the discovery, development, and commercialization of novel oncology therapeutics.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its drug candidates in various cancer indications.
- Research and Development: Cullinan Oncology invests in research and development activities to expand its pipeline and identify new therapeutic targets.
Leadership and Structure
Dr. Jennifer J. Buell is the President and CEO. The company has a typical biopharmaceutical organizational structure with departments focusing on research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- CLN-081 (rociletinib succinate): An orally available, selective, and irreversible EGFR inhibitor for the treatment of NSCLC patients with EGFR exon 20 insertion mutations. Currently in clinical development. Competitors include Takeda (Exkivity), and other companies developing EGFR inhibitors.
- CLN-619: A MICA/B-targeted antibody-drug conjugate (ADC) designed to engage and kill cancer cells expressing MICA/B. It is currently in Phase 1 clinical trials for solid tumors. Competitors include companies developing ADCs targeting other solid tumor markers.
Market Dynamics
Industry Overview
The oncology market is a large and growing market driven by the aging population, increasing incidence of cancer, and advancements in cancer diagnostics and therapeutics. Competition is intense, with numerous companies developing novel cancer therapies.
Positioning
Cullinan Oncology aims to differentiate itself through its focus on targeted therapies and its diversified pipeline. Its competitive advantage lies in its ability to identify and develop novel drug candidates targeting unmet needs in oncology.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Cullinan Oncology is positioned to capture a portion of this market through its pipeline of targeted therapies. The TAM for each individual drug being developed depends on the indications and prevalence of these specific cancers.
Upturn SWOT Analysis
Strengths
- Diversified pipeline of targeted therapies
- Experienced management team
- Strong intellectual property portfolio
- Proprietary technology platforms
Weaknesses
- Reliance on clinical trial success
- High cash burn rate
- Competition from larger pharmaceutical companies
- Limited commercialization experience
Opportunities
- Positive clinical trial results
- Regulatory approvals for drug candidates
- Strategic partnerships and collaborations
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from biosimilars and generics
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- TAK
- MRTX
- BLU
Competitive Landscape
Cullinan Oncology operates in a highly competitive market with numerous companies developing novel cancer therapies. Its success depends on its ability to differentiate itself through its targeted therapies and its diversified pipeline.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is measured by pipeline progress and clinical trial advancements.
Future Projections: Future growth is dependent on the success of its clinical trials and regulatory approvals. Analyst estimates vary depending on the perceived likelihood of success.
Recent Initiatives: Recent initiatives include advancing its lead drug candidates through clinical trials, expanding its pipeline through strategic collaborations, and strengthening its intellectual property portfolio.
Summary
Cullinan Oncology is a clinical-stage biopharmaceutical company with a promising pipeline of targeted cancer therapies. Its success hinges on positive clinical trial results and regulatory approvals. High cash burn rate and intense competition are key risks. They have strong strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cullinan Oncology LLC
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-01-08 | President, CEO & Director Mr. Nadim Ahmed | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://cullinantherapeutics.com |
Full time employees 111 | Website https://cullinantherapeutics.com | ||
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.